Skip to main content

Table 2 Best symptom and functionality response while receiving GXR, by psychiatric comorbidities of interest (post-hoc analyses)

From: A retrospective medical chart review of clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder treated with guanfacine extended-release in routine Canadian clinical practice

Comorbidity (MedDRA preferred term) Improvement, n (%)a
ADHD symptom assessmentb Functionality assessmentb
School performance Homelife
Oppositional defiant disorder, n = 92 64 (69.6) 54 (58.7) 51 (55.4)
Learning disability, n = 70 52 (74.3) 51 (72.9) 48 (68.6)
Anxiety, n = 53 39 (73.6) 38 (71.7) 36 (67.9)
Autism spectrum disorder, n = 35 24 (68.6) 24 (68.6) 21 (60.0)
  1. ADHD attention-deficit/hyperactivity disorder, GXR guanfacine extended-release, MedDRA Medical Dictionary for Regulatory Activities
  2. aPercentages were calculated using the number of patients in the respective comorbidity categories as denominator
  3. bGeneral physician assessment